Overview

Chikungunya virus (CHIKV) is a type of alphavirus endemic to tropical and subtropical regions of Africa, Asia, and the Americas, though occasional outbreaks have been reported in other areas. According to the World Health Organization, CHIKV has been identified in over 110 countries. CHIKV is carried by Aedes aegypti and Aedes albopictus mosquitoes. These mosquito species have spread into new areas, including Southern California, in recent years. 

Chikungunya disease symptoms usually begin 8 to 12 days after a person is bitten by an infected mosquito. Chikungunya patients will often develop a sudden fever, followed by severe joint pain—which can last days, months, or years. Patients can also develop flu-like symptoms and rashes. Heart problems and neurological complications have also been reported. The disease is rarely fatal, but the symptoms can be debilitating. Young babies, including newborns infected at birth, and the elderly, are at most risk of severe Chikungunya symptoms and death.

There is vaccine and no specific treatment for CHIKV infection. The disease can also be difficult to diagnose properly because the symptoms are very similar to dengue fever and Zika infection.

Our Approach

Researchers at La Jolla Institute for Immunology (LJI) are investigating how CHIKV infects cells and how the immune system responds to a CHIKV attack.

LJI Research Assistant Professor Daniela Weiskopf, Ph.D., and LJI Professor Alessandro Sette, Dr.Biol.Sci., are investigating how the immune system’s T cells recognize and target CHIKV. Their goal is to uncover which sites on the virus, called “epitopes,” prompt a strong response from human T cells. Dr. Weiskopf is also working with patient samples from a 2014-2015 CHIKV outbreak in Colombia to learn more about T cell activity in people who were diagnosed with the disease. This research is a key step in developing vaccines that trigger a protective T cell response.

A critical tool in this CHIKV research is the Immune Epitope Database (IEBD), home of expertly curated data and cutting-edge tools to analyze how the immune system recognizes and responds infectious agents and allergens. The IEDB is directed by Dr. Sette and LJI Professor Bjoern Peters, Ph.D. Scientists around the world have submitted their data on CHIKV infections and immune responses to the IEDB.

LJI Professor, President, and CEO Erica Ollmann Saphire, Ph.D., MBA, is investigating how human antibodies target viruses such an CHIKV and related alphaviruses. Her laboratory uses high-resolution imaging techniques such as cryo-electron microscopy to map viral structures and uncover where viruses are vulnerable to neutralizing antibodies.

Learn more:

LJI Center for Vaccine Innovation

Article: Delivering better vaccines

Article: All creatures great and really, really small

Article: Four science stars on the fast-track to impact

Related News

Labs

Daniela Weiskopf, Ph.D.
Assistant Professor
Center for Sex-based Differences in the Immune System, Center for Vaccine Innovation
Jul 8, 2020
Saphire Lab

Erica Ollmann Saphire, Ph.D., MBA, studies, at the molecular level, how and why viruses are pathogenic. This work provides the roadmap for medical defense.

Read More
Erica Ollmann Saphire, Ph.D., MBA
Professor, President & Chief Executive Officer
Center for Autoimmunity and Inflammation, Center for Cancer Immunotherapy, Center for Sex-based Differences in the Immune System, Center for Vaccine Innovation
Jul 2, 2020
Sette Lab

Alessandro Sette, Dr.Biol.Sci., defines in chemical terms the specific structures (epitopes) that the immune system recognizes and uses this knowledge to measure and understand immune responses.

Read More
Alessandro Sette, Dr.Biol.Sci.
Professor
Center for Autoimmunity and Inflammation - Director, Center for Cancer Immunotherapy, Center for Vaccine Innovation